Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20, 2022 12:09 pm

by Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer

May 24, 2021 3:00 pm

By Jennifer Southall

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical OncologyRead more

Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

March 26, 2021 1:00 pm

Ixabepilone plus bevacizumab yielded responses in a third of patients.

By Ian Ingram

Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.

Median progression-free … Read more

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

March 22, 2021 4:00 pm

By Chase Doyle

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more

Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

March 21, 2021 5:00 pm

Responses in 37% of patients with AVB-500, higher without prior bevacizumab.

By Charles Bankhead

More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more

REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer

February 25, 2021 5:00 pm

For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more

Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer

February 23, 2021 6:00 pm

By Matthew Stenger

In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more

New Combination Treatment for Recurrent Ovarian Cancer Shows Positive Outcomes

November 19, 2020 5:00 pm

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

In a new article in JAMA Oncology, the … Read more

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

June 5, 2020 8:00 am

By Audrey Sternberg

The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.

The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib … Read more

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020 5:00 pm

By Susan Moench, PhD, PA-C

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Early results from a single-arm phase 1b study conducted in … Read more

FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer

May 8, 2020 10:00 am

By Beth Fand Incollingo

The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 26, 2020 10:00 am

By Jason M. Broderick

An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer

June 4, 2019 6:00 pm

By Ian Ingram

Benefit seen across all subgroups for patients with platinum-sensitive disease.

Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more

Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells

May 15, 2019 6:00 pm

According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more

Study Shows Ovarian Cancer Survival Increase

May 3, 2019 5:00 pm

A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more

Still No Benefit of IP Chemo for Ovarian Cancer

April 24, 2019 5:00 pm

By Charles Bankhead

No PFS or OS benefit, more toxicity with IP verses IV regimens

Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more

Novel Technique Potentially More Effective in Fighting Against Ovarian Cancer

November 8, 2018 9:00 am

Instead of destroying a tumors’ blood supply, a first-ever University of Guelph study has proven that opening up the vessels is potentially more effective when it comes to fighting ovarian cancer.

This is because open vessels provide a clear pathway … Read more